Advertisement
Cardiovascular
Subscribe to Cardiovascular
View Sample

FREE Email Newsletter

Meaningful Use Certification Awarded to Press Ganey's Quality Performer(SM)

August 1, 2011 9:43 am | by Bio-Medicine.Org | News | Comments

SOUTH BEND, Ind., Aug. 1, 2011 /- Press Ganey's Quality Performer - Hospital eMeasures attained electronic health record (EHR) clinical quality measures module certification on July 27, 2011. The Hospital eMeasures functionality within Quality Performer – a comprehensive clinical...

Global Mercury Treaty May Include Ban on Mercury in Medicine

August 1, 2011 8:39 am | by Bio-Medicine.Org | News | Comments

SILVER SPRING, Md., Aug. 1, 2011 /PRNewswire-USNewswire/ – CoMeD – On Friday, July 22, 2011, the United Nations Environment Programme (UNEP) distributed a revised text for its comprehensive global treaty on mercury .  Advocates for mercury-free drugs were gratified to see...

EGT Transfers cGMP Vector for Gene Therapy Trial

July 29, 2011 5:35 am | by Bio-Medicine.Org | News | Comments

CHICAGO, July 29, 2011 /- Errant Gene Therapeutics, LLC ("EGT"), a pioneering boutique drug development firm specializing in Rare Diseases, announced the transfer of its clinical grade lentiviral vector, TNS 9.55.3, to Memorial Sloan Kettering Cancer Center ("MSKCC"). TNS 9.55.3...

Advertisement

Anthera Pharmaceuticals Reports 2011 Second Quarter Financial Results and Operational Update

July 29, 2011 5:34 am | by Bio-Medicine.Org | News | Comments

HAYWARD, Calif., July 29, 2011 /- Anthera Pharmaceuticals, Inc. (Nasdaq: ANTH ), today announced financial results and business highlights for the quarter ended June 30, 2011. Financial Results: Total operating expenses for the second quarter ended June 30, 2011 were $22.7 million, as...

Kensey Nash Corporation Announces Its Fourth Quarter and Fiscal Year End 2011 Earnings Release Date and Teleconference

July 28, 2011 9:38 pm | by Bio-Medicine.Org | News | Comments

EXTON, Pa., July 28, 2011 /- Kensey Nash Corporation (Nasdaq: KNSY ) today announced that it will release its earnings results for its fourth quarter and fiscal year ended June 30, 2011 at 7:00 A.M. Eastern Time on Thursday, August 18, 2011.   Joe Kaufmann, President and CEO, will be...

Data Presented at American Association for Clinical Chemistry Meeting Show Many Americans May Have Low Vitamin D Levels

July 28, 2011 7:36 am | by Bio-Medicine.Org | News | Comments

ATLANTA, July 28, 2011 /- Data presented this week at the American Association for Clinical Chemistry (AACC) meeting showed that many people have low vitamin D levels and that testing individuals at risk may be beneficial. According to published data from the Third National Health and...

VeraLight Announces CE Mark Approval of the SCOUT DS® for Noninvasive Diabetes Screening

July 28, 2011 7:36 am | by Bio-Medicine.Org | News | Comments

ALBUQUERQUE, N.M., July 28, 2011 /- VeraLight Inc., a privately held medical device company, today announced its SCOUT DS® Device was granted CE Mark approval for noninvasive diabetes screening. The easy to operate device needs no blood, does not require fasting, and yields an...

CryoLife Reports Record Revenues for the Second Quarter and First Six Months of 2011

July 28, 2011 7:36 am | by Bio-Medicine.Org | News | Comments

ATLANTA, July 28, 2011 /- CryoLife, Inc. (NYSE: CRY ), a leading tissue processing and medical device Company focused on cardiac and vascular surgery, announced today its results for the second quarter and first six months of 2011.  Revenues for the second quarter were a record $29.4...

Advertisement

Lexicon's IBS Drug Candidate, LX1033, Successfully Completes Phase 1 Clinical Trial

July 28, 2011 3:38 am | by Bio-Medicine.Org | News | Comments

THE WOODLANDS, Texas, July 28, 2011 /- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX ), a biopharmaceutical company focused on discovering breakthrough treatments for human disease, announced today that it has successfully completed a Phase 1 clinical trial of LX1033, an orally-delivered...

Covidien Announces Data on Pipeline(R) Embolization Device for Uncoilable or Failed Aneurysms

July 27, 2011 5:43 pm | by Covidien | News | Comments

Clinical study shows device safety and effectiveness COLORADO SPRINGS, Colo., Jul 27, 2011 (BUSINESS WIRE) --Covidien (NYSE:COV), a leading global provider of healthcare products, today announced the results of the PUFS (Pipeline for Uncoilable or Failed AneurysmS) clinical study at the...

Boston Scientific Announces Five-Year, $150 Million Investment in China to Accelerate Commercial Expansion

July 27, 2011 5:42 am | by Boston Scientific | News | Comments

Investment to support development of local manufacturing capabilities and training center

UK Cardiovascular Monitoring Systems - Market Trends Till 2016

July 27, 2011 1:38 am | by Bio-Medicine.Org | News | Comments

NEW YORK, July 27, 2011 /- Reportlinker.com announces that a new market research report is available in its catalogue: UK Cardiovascular Monitoring Systems - Market Trends Till 2016...

India Cardiac Catheters and Guidewires - Market Trends Till 2016

July 27, 2011 1:37 am | by Bio-Medicine.Org | News | Comments

NEW YORK, July 27, 2011 /- Reportlinker.com announces that a new market research report is available in its catalogue: India Cardiac Catheters and Guidewires - Market Trends Till 2016...

Advertisement

China Cardiac Catheters and Guidewires - Market Trends Till 2016

July 26, 2011 1:46 am | by Bio-Medicine.Org | News | Comments

NEW YORK, July 26, 2011 /- Reportlinker.com announces that a new market research report is available in its catalogue: China Cardiac Catheters and Guidewires - Market Trends Till 2016...

Glucose Meter Can Detect Cocaine, Uranium in Blood

July 25, 2011 8:36 pm | by Massachusetts Institute of Technology | News | Comments

Creative chemistry lets an inexpensive, off-the-shelf meter measure a variety of medically important targets.

Genetic Testing Can Help the US Cut Costs and Improve Health Care

July 25, 2011 4:44 am | by Bio-Medicine.Org | News | Comments

WASHINGTON, July 25, 2011 /PRNewswire-USNewswire/ -- Genetic testing made possible by the mapping of the human genome can help the US cut costs and create jobs while at the same time improving survival rates for such diseases as cancer, HIV, and heart disease. This according to Alan...

Cellestis Responds to World Health Organization Guidance on Use of Blood Tests for Active Tuberculosis

July 25, 2011 1:39 am | by Bio-Medicine.Org | News | Comments

MELBOURNE, Australia, July 25, 2011 /- A new policy recommendation released on 20 July by the World Health Organization (WHO) warns against the use of serological (blood) tests to diagnose active tuberculosis (TB). Serological tests measure antibodies to TB in serum and are different to...

Children's Hospital, Genethon get FDA OK for gene therapy trial

July 22, 2011 8:41 am | by Mass High Tech: The Journal of New England Technology | News | Comments

Children's Hospital Boston has won approval from the U.S. Food and Drug Administration for a gene therapy trial in conjunction with French biotech Genethon to treat the rare immunodeficiency known as Wiskott-Aldrich syndrome.

Quanterix Digital Immunoassay for Prostate Specific Antigen Improves Analytical Performance

July 21, 2011 6:38 am | by Bio-Medicine.Org | News | Comments

CAMBRIDGE, Mass., July 21, 2011 /- Quanterix Corporation, an in-vitro diagnostics (IVD) company providing life science researchers and IVD labs single molecule technology with unprecedented sensitivity and precision, announced that the analytical performance of AccuPSA™, a...

Nearly 7,000 Participate in Cardinal Health's Largest-Ever Annual Trade Show for Independent Pharmacies

July 20, 2011 6:40 am | by Bio-Medicine.Org | News | Comments

LAS VEGAS, July 20, 2011 /- Cardinal Health today announced that this week's Retail Business Conference (RBC), its annual, national trade show for independent pharmacies, is the largest in the event's 20+ year history, with nearly 7,000 attendees. This year's event, taking place July...

Frantz Medical Group Subsidiary, VasoStar, Awarded $1 Million Research Grant

July 20, 2011 6:40 am | by Bio-Medicine.Org | News | Comments

CLEVELAND, July 20, 2011 /- One of Frantz Medical Group's (FMG) subsidiaries, VasoStar Inc., Mentor, Ohio  today announced that it has been awarded an Ohio Third Frontier grant to further develop and commercialize a novel electromagnetic guidewire system for penetrating through...

CryoLife Announces Release Date and Teleconference Call Details for 2011 Second Quarter Financial Results

July 20, 2011 6:40 am | by Bio-Medicine.Org | News | Comments

ATLANTA, July 20, 2011 /- CryoLife, Inc. (NYSE: CRY ), a leading tissue processing and medical device Company focused on cardiac and vascular surgery, announced today that 2011 second quarter financial results will be released on Thursday, July 28, 2011.  On that day, the Company...

Provent® Sleep Apnea Therapy Now Available in India

July 19, 2011 9:37 pm | by Bio-Medicine.Org | News | Comments

BELMONT, Calif. and HYDERABAD, India, July 20, 2011 /- Ventus Medical is pleased to announce the Indian launch of its proprietary Provent® Sleep Apnea Therapy, an innovative, non-invasive treatment for obstructive sleep apnea (OSA). Orbees Business Solutions Pvt. Ltd. will be the...

OrbusNeich's Genousâ„¢ Stent Enables Early and Safe Discontinuation of Dual Antiplatelet Therapy in High-Risk Patients Requiring Nondeferrable, Non-Cardiac Surgery

July 18, 2011 10:51 am | by Bio-Medicine.Org | News | Comments

HONG KONG, July 18, 2011 /- Data from high-risk patients requiring early discontinuation of dual antiplatelet therapy (DAPT) due to nondeferrable, non-cardiac surgery show good short- and long-term clinical and safety outcomes following treatment with OrbusNeich's Genous Stent, according...

Crestor and Zocor Drugs Linked to Muscle Degeneration, Rhabdomyolysis

July 15, 2011 8:42 am | by Bio-Medicine.Org | News | Comments

EDISON, N.J., July 15, 2011 /- Crestor and Zocor are widely-used prescription strength drugs designed to lower "bad cholesterol". Both drugs are classified as "statins", medicine which lowers blood cholesterol levels by inhibiting HMG-CoA reductase. This group of drugs has had a...

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading